Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

INHANCE Stemless Reverse Shoulder IDE

2. november 2026 oppdatert av: DePuy Orthopaedics

Randomisert, prospektiv, multisenterstudie av INHANCE Stemless Total Reverse Shoulder System

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

There is one primary effectiveness endpoint and there are three primary safety endpoints:

  1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative

  2. Primary safety endpoint(s):

    1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
    2. No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
    3. No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years

The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

Studietype

Intervensjonell

Registrering (Faktiske)

168

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Florida
      • Atlantis, Florida, Forente stater, 33462
        • Orthopedic Center of Palm Beach County
    • Massachusetts
      • Waltham, Massachusetts, Forente stater, 02451
        • Boston Bone & Joint Institute BBJI Formerly BSSC
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49503
        • Trinity Health Grand Rapids
    • Missouri
      • Columbia, Missouri, Forente stater, 65201
        • Missouri Orthopaedic Institute (MOI)
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28207
        • OrthoCarolina Research Institute Charlotte
      • Raleigh, North Carolina, Forente stater, 27609
        • Duke Orthopaedics of Raleigh
    • Ohio
      • Akron, Ohio, Forente stater, 44333
        • Crystal Clinic Orthopaedic Center
      • Cincinnati, Ohio, Forente stater, 45219
        • Lindner Research Center
      • Cleveland, Ohio, Forente stater, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Slocum Center for Orthopaedics and Sports Medicine
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forente stater, 18015
        • St. Luke's University Health Network
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rothman Orthopaedics Institute
    • Tennessee
      • Columbia, Tennessee, Forente stater, 38401
        • MTBJ a division of Tennessee Orthaepedic Alliance
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • University of Utah
    • Virginia
      • Fredericksburg, Virginia, Forente stater, 22408
        • Mary Washington Orthopedics in affiliation with FOA

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

22 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
  2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
  3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
  4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
  5. Individuals who are a minimum age of 22 years at the time of consent.
  6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.

Exclusion Criteria:

  1. BMI > 40 kg/m2
  2. Individuals have active, uncontrolled local infection or systemic infection.
  3. Patients who have not reached skeletal maturity, regardless of age.
  4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
  5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
  7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
  8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
  9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
  10. Individuals who are bedridden per the Investigator's determination.
  11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
  15. Patient has a medical condition with less than 2 years life expectancy.
  16. Patients who are known to be pregnant or breastfeeding.
  17. Known polyethylene and/or metal sensitivity or allergy.
  18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
  19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
  20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: INHANCE Stemless Reverse

INHANCE(TM) Stemless Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Aktiv komparator: INHANCE Stemmed Reverse

INHANCE(TM) Stemmed Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Constant Murley Score (CMS)
Tidsramme: Pre-op, 2 years

Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 2 years
Removal of any system component
Tidsramme: 2 year

No removal of any system component

2 year
Revision of any system component
Tidsramme: 2 year

No revision of any system component

2 year
Reoperation of any system component
Tidsramme: 2 year

No reoperation of any system component

2 year
Supplemental Fixation of any system component
Tidsramme: 2 year

No supplemental fixation of any system component

2 year
Radiolucent Lines (Humeral & Glenoid)
Tidsramme: 2 year

No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones

2 year
Migration and Tilt (Humeral & Glenoid)
Tidsramme: 2 year

No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component

2 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Constant Murley Score (CMS)
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year, 2 year
EQ-5D-5L and EQ-VAS
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Survivorship
Tidsramme: 2 year

Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method.

2 year
Complications
Tidsramme: 2 year

The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs

2 year

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Constant Murley Score (CMS)
Tidsramme: Pre-op, 3-month, 6-month, 1 year

Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year
EQ-5D-5L and EQ-VAS
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Range of Motion
Tidsramme: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative

Pre-op, 3-month, 6-month, 1 year, 2 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. mars 2025

Primær fullføring (Antatt)

10. november 2027

Studiet fullført (Antatt)

30. oktober 2028

Datoer for studieregistrering

Først innsendt

27. februar 2024

Først innsendt som oppfylte QC-kriteriene

15. mars 2024

Først lagt ut (Faktiske)

21. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • DSM202108
  • DSM202108 (Annen identifikator: DePuy Orthopaedics)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .